Analyst Reco. Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
21.13 ^USD	-0.70%		+0.76%	-2.22%

08/04	Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	CI
28/03	Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	20/03	MT
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform From Sector Outperform, Cuts Price Target to $23 From $36	31/01	MT
JPMorgan Adjusts Syndax Pharmaceuticals Price Target to $37 From $38, Maintains Overweight Rating	24/11	MT
BofA Securities Starts Syndax Pharmaceuticals at Buy With $29 Price Target	25/23/25	MT
Scotiabank Cuts Syndax Pharmaceuticals Price Target to $36 From $39, Maintains Sector Outperform Rating	03/23/03	MT
HC Wainwright Adjusts Syndax Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	02/23/02	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $33 From $36, Keeps Overweight Rating	16/23/16	MT
Scotiabank Starts Syndax Pharmaceuticals at Sector Perform With $39 Price Target	27/23/27	MT
Barclays Adjusts Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	26/23/26	MT
B. Riley Raises Syndax Pharmaceuticals' Price Target to $36 From $34 on Heels of Clinical Update for cGVHD, Keeps Buy Rating	25/23/25	MT
Guggenheim Adjusts Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating	24/23/24	MT
Stifel Adjusts Price Target on Syndax Pharmaceuticals to $38 From $37, Maintains Buy Rating	24/23/24	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $32, Maintains Overweight Rating	24/23/24	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $38 From $36, Keeps Buy Rating	24/23/24	MT
Guggenheim Initiates Syndax Pharmaceuticals With Buy Rating, $40 Price Target	11/23/11	MT
BTIG Adjusts Price Target on Syndax Pharmaceuticals to $35 From $34, Keeps Buy Rating	26/23/26	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $31 From $32, Keeps Buy Rating	10/23/10	MT
HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $36 From $33, Keeps Buy Rating	09/23/09	MT
JPMorgan Adjusts Price Target on Syndax Pharmaceuticals to $36 From $41, Maintains Overweight Rating	07/23/07	MT
Citigroup Adjusts Price Target on Syndax Pharmaceuticals to $32 From $29, Maintains Buy Rating	02/23/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Analyst Reco.

Filters